A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer

PHASE3RecruitingINTERVENTIONAL

Enrollment

520

Participants

Timeline

Start Date

December 16, 2024

Primary Completion Date

December 16, 2026

Study Completion Date

December 16, 2027

Conditions

Early or Locally Advanced HER2-positive Breast Cancer

Interventions

DRUG

KN026

DRUG

HB1801

DRUG

Pertuzumab

DRUG

Trastuzumab

DRUG

Docetaxel

DRUG

Carboplatin

Trial Locations (1)

RECRUITING

Clinical Trials Information Group, Shanghai

All Listed Sponsors

lead

Shanghai JMT-Bio Inc.

INDUSTRY